NAD+ Repletion Reverses Heart Failure With Preserved Ejection Fraction

  • Circ Res. 2021 May 28;128(11):1629-1641. doi: 10.1161/CIRCRESAHA.120.317046.
Dan Tong  1 ,  Gabriele G Schiattarella  1 ,  Nan Jiang  1 ,  Francisco Altamirano  1 ,  Pamela A Szweda  1 ,  Abdallah Elnwasany  1 ,  Dong I Lee  2 ,  Heesoo Yoo  1 ,  David A Kass  2 ,  Luke I Szweda  1 ,  Sergio Lavandero  1  3 ,  Eric Verdin  4 ,  Thomas G Gillette  1 ,  Joseph A Hill  1  5
Affiliations
  • 1. Internal Medicine (Cardiology) (D.T., G.G.S., N.J., F.A., P.A.S., A.E., H.Y., L.I.S., S.L., T.G.G., J.A.H.), University of Texas Southwestern Medical Center, Dallas, TX.
  • 2. Department of Medicine (Cardiology), Johns Hopkins University School of Medicine, Baltimore MD (D.I.K., D.A.K.).
  • 3. Advanced Center for Chronic Diseases (ACCDiS) & Corporacion Estudios Cientificos de las Enfermedades Cronicas (CECEC), Faculty of Chemical & Pharmaceutical Sciences & Faculty of Medicine, University of Chile, Santiago (S.L.).
  • 4. Bulk Institute for Research on Aging, Novato, CA (E.V.).
  • 5. Molecular Biology (J.A.H.), University of Texas Southwestern Medical Center, Dallas, TX.
PMID: 33882692 DOI: 10.1161/CIRCRESAHA.120.317046
Abstract

[Figure: see text].

Keywords
NAD; acetylation; cardiomyopathy; heart failure; mitochondria.
Products